Vizantin, 6, 6′-bis-O-(3-nonyldodecanoyl)-α, α′-trehalose, was developed as a safe immunostimulator on the basis of a structure–activity relationship (SAR) study with trehalose 6, 6′-dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16–F0 melanoma cells. Because ...
